Morphine metabolites are involved in various ways in determining the complex effects of morphine, both favourable and adverse, and may complicate the clinical use of morphine in the treatment of cancer pain. The production and effects of the principal morphine metabolites, morphine-3-glucuronide and morphine-6-glucuronide, in both normal and pathological states have been reviewed in the current literature. Therapeutic implications are also reviewed on the basis of experimental and clinical reports. The presence of these metabolites should be recognized in the chronic treatment of cancer pain with morphine, especially in the presence of renal impairment, and should be considered to have an important influence on opioid responsiveness, defined as a balance between the achievement of an optimal analgesia and the occurrence of adverse effects.
Hanks GW, De Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. Br Med J1996; 312: 826–828.
2.
Faura CC, Moore RA, Horga JF, Hand CW, McQuay HJ. Morphine and morphine-6-glucuronide plasma concentrations and effects in cancer pain. J Pain Symptom Manage1996; 11: 95–102.
3.
McQuay HJ, Carroll D, Faura CC, Cavaghan DJ, Hand CW, Moore RA. Oral morphine in cancer pain: influence on morphine and metabolite concentration. Clin Pharmacol Ther1990; 48: 236–244.
4.
Osborne R, Joel S, Trew D, Slevin M. Morphine and metabolite behavior after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol Ther1990; 47: 12–19.
5.
Sawe J. High-dose morphine and methadone in cancer patients: clinical considerations of oral treatment. Clin Pharmacokin1986; 11: 87–106.
6.
Hanna MH, Peat SJ, Woodham M, Knibb A, Fung C. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth1990; 64: 547–550.
7.
Kalman S, Metcalf K, Eintrei C. Morphine, morphine-6-glucuronide, and morphine-3-glucuronide in cerebrospinal fluid and plasma after epidural administration of morphine. Reg Anesth1997; 22: 131–136.
8.
Warren DE. Practical use of rectal medications in palliative care. J Pain Symptom Manage1996; 11: 378–387.
9.
Tiseo PJ, Thaler HT, Lapin J, Inturrisi CH, Portenoy RK, Foley KM. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain1995; 61: 47–54.
10.
Peterson GM, Randall CTC, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol1990; 38: 121–124.
11.
Babul N, Darke AC. Disposition of morphine and its glucuronide metabolites after oral and rectal administration: evidence of route specificity. Clin Pharmacol Ther1993; 54: 286–292.
12.
Portenoy RK, Foley KM, Stulman J et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady-state concentrations and the consequences of renal failure. Pain1991; 47: 13–19.
13.
Osborne RJ, Joel SP, Slevin ML. Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J1986; 292: 1548–1549.
14.
Gourlay GK, Plummer JL, Cherry DA. Chronopharmacokinetic variability in plasma morphine concentrations following oral doses of morphine solution. Pain1995; 61: 375–381.
Goucke CR, Hackett LP, Ilett KF. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain. Pain1994; 56: 145–149.
17.
Hunt A, Joel S, Cloyne A, Goldman A. Establishing pharmacokinetic parameters of oral morphine and its glucuronides in children with cancer. Eighth world congress on pain. Vancouver: 17–22 August 1996: 394.
18.
Van Crutgen JT, Somogyi AA, Nation RL, Reynolds G. The effect of old age on the disposition and nociceptive response of morphine and morphine-6-glucuronide in the rat. Pain1997; 71: 199–205.
19.
Wahlstrom A, Pacifici GM, Lindstrom B, Hammar L, Rane A. Human liver morphine UDP-glucuronyl transferase enantioselectivity and inhibition by opioid congeners and diazepam. Br J Pharmacol1988; 94: 864–870.
20.
Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-6-glucuronide. Lancet1988; i: 828.
21.
D'Honneur G, Gilton A, Sandouk P, Schermann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anaesthesiology1994; 81: 87–93.
22.
Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth1993; 71: 282–290.
23.
Kaiko RK, Foley K, Grabinski PY et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol1983; 13: 150–185.
24.
Osborne R, Joel S, Grebenik K, Trew D, Slevin M. The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther1993; 54: 158–167.
25.
Jones N, Durcan T, Fung M et al. The effect of age and type of surgery on the pharmacokinetics of morphine and its active metabolite morphine-6-glucuronide. Eighth world congress on pain. Vancouver: 17–22 August 1996: 395.
De Stoutz ND, Bruera E, Suarez-Almozor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage1995; 10: 378–384.
28.
Woolf T, Samuelsson H, Hedner T. Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration. Pain1995; 62: 147–154.
29.
Portenoy RK, Khan E, Layman M et al. Chronic morphine therapy for cancer pain: plasma and cerebrospinal fluid morphine and morphine-6-glucuronide concentrations. Neurology1991; 41: 1457–1461.
30.
Hagen NA, Foley KM, Cerbone DJ, Portenoy RK, Inturrisi CE. Chronic nausea and morphine-6-glucuronide. J Pain Sympt Manage1991; 6: 125–128.
31.
Hoskin PJ, Hanks GW, Heron CW, Aherne GW. M6G and its analgesic action in chronic use. Clin J Pain1989; 5: 199–201.
32.
Woolf T, Samuelsson H, Hedner T. Concentrations of morphine and morphine metabolites in CSF and plasma during continuous subcutaneous morphine administration in cancer pain patients. Pain1996; 68: 209–216.
33.
Poulain P, Moran Ribon A, Hanks GW, Hoskin PJ, Aherne GW, Chapman DJ. CSF concentrations of morphine-6-glucuronide after oral administration of morphine. Pain1990; 41:115–116.
34.
Geisslinger G, Brune K, Kobal G, Lotsch J. Intravenous morphine-6-glucuronide (M6G) is devoid of analgesic activity in man. Pain1997; 70: 289–290.
35.
Samuelsson H, Hedner T, Venn R, Michalkiewics A. CSF and plasma concentrations of morphine and morphine glucuronides in cancer patients receiving epidural morphine. Pain1993; 46: 3–8.
36.
Nordberg G. Pharmacokinetic aspects of spinal morphine analgesia. Acta Anesthesiol Scand1984; 28: 1–38.
37.
Samuelsson H, Nordberg G, Hedner T, Lindquist J. CSF and plasma morphine concentrations in cancer patients during chronic epidural morphine therapy and its relation to pain relief. Pain1987; 30: 303–310.
38.
Bigler D, Christensen CB, Eriksen J, Jensen NH. Morphine, morphine-6-glucuronide and morphine-3-glucuronide concentrations in plasma and cerebrospinal fluid during long-term high-dose intrathecal administration. Pain1990; 41: 15–18.
39.
Frances B, Gout R, Monsarrat B, Cros J, Zajac JM. Further evidence that morphine-6-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther1992; 262: 25–31.
40.
Frances B, Gout R, Campistron G, Panconi E, Cros J. Morphine-6-glucuronide is more mu-selective and potent in analgesic tests than morphine. Progr Clin Biol Res1990; 328: 477–480.
41.
Pasternak GW, Bodnar RJ, Clark JA, Inturrisi CE. Morphine-6-glucuronide: a potent mu-agonist. Life Sci1987; 41: 2845–2849.
42.
Sullivan AF, McQuay HJ, Bailey D, Dickenson AH. The spinal antinociceptive actions of morphine metabolites, morphine-6-glucuronide and normorphine, in the rat. Brain Res1989; 482: 219–224.
43.
Peat SJ, Hanna MH, Woodham M, Knibb AA, Ponte J. Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain1991; 45: 101–104.
44.
Thompson P, Hucks D, McLoughlin L, Grossman A, Rees L, Slevin M. Comparative opiate receptor affinities of morphine and its active metabolite morphine-6-glucuronide. Br J Cancer1990; 628: 484.
45.
Smith GD, Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in rat. Pain1995; 52: 51–60.
46.
Gong OL, Hedner J, Bjorkman R, Hedner T. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain1992; 48: 249–255.
47.
Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res1989; 174: 263–271.
48.
Gong OL, Hedner T, Hedner J, Bjorkman R, Nordberg G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-3-glucuronide and morphine-6-glucuronide. Eur J Pharmacol1992; 193: 47–56.
49.
Smith MT, Watt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci1990; 47: 579–585.
50.
Faura CC, Olaso MJ, Cabanes CG, Horga JF. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?Pain1996; 65; 25–30.
51.
Lipkowski AW, Carr DB, Langlade A, Osgood PF, Szyfelbein SK. Morphine-3-glucuronide: silent regulator of morphine actions. Life Sci1994; 55: 149–154.
52.
Smith MJ, Smith G. Reply. Pain1996; 65: 286.
53.
Hewett K, Dickenson AH, McQuay HJ. Lack of effect of morphine-3-glucuronide on spinal antinociceptive actions of morphine in the rat: an electrophysiological study. Pain1993; 53: 59–63.
54.
Suzuki N, Kalso E, Rosenberg PH. Intrathecal morphine-3-glucuronide does not antagonize spinal antinociception by morphine or morphine-6-glucuronide in rats. Eur J Pharmacol1993; 249: 247–250.
55.
Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronization of morphine. J Pharmacobiodyn1991; 14: 187–193.
56.
Halliday AJ, Barlett SE, Smith MT. Quantification of the differential CNS excitatory effects of morphine-3-glucuronide (M3G) in specific regions of the rat brain. Eighth world congress on pain. Vancouver: 17–22 August 1996: 396.
57.
Bartlett SE, Dodd PR, Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol1994; 75: 73–81
58.
Werz MA, MacDonald RL. Opiate alkaloids antagonize post-synaptic glycine and GABA responses: correlation with convulsant action. Brain Res1982; 236: 107–119.
59.
Bowsher D. Paradoxical pain. Br Med J1993; 306: 473.
60.
Morley JS, Miles JB, Bowsher D. Paradoxical pain. Lancet1992; 340: 1045.
61.
Morley JS, Watt J, Wells JC, McKibbin PE, Seabra L, Miles JB. Paradoxical and other pain uncontrolled by morphine. In: Gebhart GK, Hammond DL, Jensen TS eds. Proceedings of the seventh world congress on pain. Progress in pain research and management.. Vol. 2. Seattle, WA: IASP Press, 1994: 621–630.
62.
Parris WCV, Janicki PK, Johnson B, Livengood J, Mathews L. Persistent pain associated with long-term intrathecal morphine administration. South Med J1996; 89: 417–419.
63.
Samuelsson H, Hadner T. Pain characterisation in cancer patients and analgesic response to epidural morphine. Pain1991; 46: 3–8.
64.
Cramond T, Stuart G. Intraventricular morphine for intractable pain of advanced cancer. J Pain Symptom Manage1993; 8: 465–473.
65.
Cramond T, Wright AWE, Stuart GS, Smith M. Plasma and CSF concentrations of morphine, M3G and M6G in cancer patients receiving morphine by intracerebroventricular route. Seventh world congress on pain. Paris: 1993: 531.
66.
Bruera E, Pereira J. Neuropsychiatric toxicity of opioids. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z eds. Proceedings of the eighth world congress on pain. Progress in pain research and management. Vol. 8. Seattle, WA: IASP Press, 1997: 717–738.
67.
Sawe J, Svennson JO, Odar-Cederlof I. Kinetics of morphine in patients with renal failure. Lancet1985; ii: 211–213.
68.
Woolf J, Bigler D, Christensen CB, Rasmussen SN, Andersen HB, Tonnesen KH. Influence of renal function on the elimination of morphine and morphine glucuronides. Eur J Clin Pharmacol1988; 34: 353–357.
69.
Woolner DF, Winter D, Frendin TJ, Begg EJ, Lynn KL, Wright GJ. Renal failure does not impair the metabolism of morphine. Br J Clin Pharmacol1986; 22: 55–59.
70.
Sjogren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting with other opioid agonists. Pain1994; 59: 313–316.
71.
Sjogren P, Jonsson T, Jensen NH, Drenck NE, Jensen TS. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain1993; 55: 93–97.
72.
De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain1991; 47: 337–339.
73.
Parkinson SK, Bailey SL, Little WL, Mueller JB. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology1990; 72: 743–745.
74.
Kloke M, Bingel U, Seeber S. Complications of spinal opioid therapy: myoclonus, spastic muscle tone and spinal jerking. Support Care Cancer1994; 2: 249–252.
75.
Appelgren L, Nordborg C, Sjoberg M, Karlsson PA, Nitescu P, Curelaru I. Spinal epidural metastasis: implications for spinal analgesia to treat refractory cancer pain. J Pain Symptom Manage1997; 13: 25–42.
76.
Potter JM, Reid DB, Shaw RJ, Hackett PP, Hickmann PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. Br Med J1989; 299: 150–153.
77.
Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage1995; 10: 287–291.
